No posts to display

Latest news

Tecentriq, chemo combo approved in US for ES-SCLC

Tecentriq, chemo combo approved in US for ES-SCLC

Tecentriq has been approved in the US in combination with chemotherapy for the first-line treatment of adults with extensive small cell lung cancer (ES-SCLC)....
Imara raises funds to advance sickle cell treatment

In brief: Imara raises funds to advance sickle cell treatment

Massachusetts biopharma, Imara, has raised $63 million in Series B funding to advance its treatment of sickle cell disease. Specifically,...
Orphan status for AstraZeneca’s potential IPF treatment

Orphan status for AstraZeneca’s potential IPF treatment

Saracatinib, a potential new treatment from AstraZeneca for idiopathic pulmonary fibrosis (IPF), has been granted Orphan Drug Designation (ODD) in the US.